This study focuses on a new drug called disitamab vedotin (DV), which helps fight cancer cells in solid tumors. Solid tumors are lumps of cancer cells. They can grow or spread in the body, and when they do, it's called advanced or metastatic cancer. The research is for people diagnosed with cancers that have a special marker called HER2. These cancers include head and neck, lung, ovarian, or endometrial cancers.

DV is an experimental drug that acts like a smart bomb. It's designed to find cancer cells and destroy them. Everyone in this study will receive DV every two weeks to see if it helps reduce tumors and how safe it is. Researchers will also check for any side effects, which are changes in the body caused by the drug that are not related to cancer treatment.

• Study Duration: Participants will receive DV once every two weeks.
• Eligibility: Specific types of cancer and HER2 marker presence needed.
• Considerations: Participants must be aware of the possible side effects and requirements before joining.